2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Firmonertinib

Firmonertinib  (Synonyms: Alflutinib; Furmonertinib; AST2818)

Cat. No.: HY-112870 Purity: 99.89%
COA
SDS
Handling Instructions Technical Support

Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

For research use only. We do not sell to patients.

CAS No. : 1869057-83-9

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Firmonertinib:

Firmonertinib Related Antibodies

Top Publications Citing Use of Products

    Firmonertinib purchased from MedChemExpress. Usage Cited in: JTO Clin Res Rep. 2023 Nov 27;5(1):100614.

    Dose-response proliferation assays (percent viability) for cell lines harboring EGFR-D770_N771insSVD in the absence or presence of EGFR-T790M or EGFR-C797S after exposure to increasing concentrations of Furmonertinib (Firmonertinib).

    View All EGFR Isoform Specific Products:

    View All Isoforms
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation[1].

    IC50 & Target[1]

    EGFR

     

    In Vitro

    Firmonertinib is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Firmonertinib Related Antibodies
    Clinical Trial
    Molecular Weight

    568.59

    Formula

    C28H31F3N8O2
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (175.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7587 mL 8.7937 mL 17.5874 mL
    5 mM 0.3517 mL 1.7587 mL 3.5175 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.89%

    SDS (393 KB)

    COA (257 KB) HNMR (268 KB) LCMS (95 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7587 mL 8.7937 mL 17.5874 mL 43.9684 mL
    5 mM 0.3517 mL 1.7587 mL 3.5175 mL 8.7937 mL
    10 mM 0.1759 mL 0.8794 mL 1.7587 mL 4.3968 mL
    15 mM 0.1172 mL 0.5862 mL 1.1725 mL 2.9312 mL
    20 mM 0.0879 mL 0.4397 mL 0.8794 mL 2.1984 mL
    25 mM 0.0703 mL 0.3517 mL 0.7035 mL 1.7587 mL
    30 mM 0.0586 mL 0.2931 mL 0.5862 mL 1.4656 mL
    40 mM 0.0440 mL 0.2198 mL 0.4397 mL 1.0992 mL
    50 mM 0.0352 mL 0.1759 mL 0.3517 mL 0.8794 mL
    60 mM 0.0293 mL 0.1466 mL 0.2931 mL 0.7328 mL
    80 mM 0.0220 mL 0.1099 mL 0.2198 mL 0.5496 mL
    100 mM 0.0176 mL 0.0879 mL 0.1759 mL 0.4397 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Firmonertinib Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Firmonertinib1869057-83-9Alflutinib Furmonertinib AST2818AST2818AST 2818AST-2818EGFREpidermal growth factor receptorErbB-1HER1T790Mesistant mutationNSCLCcancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Firmonertinib
    Cat. No.:
    HY-112870
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.